why choose us

First received: November 14, 2022

Clinical Trial: Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

Study Status: Completed

Recruit Status: RECRUITING

Condition: Diffuse Large B-Cell Lymphoma

Study Type: INTERVENTIONAL


Official Title: A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies

Brief Summary: B-cell malignancies are a group of cancers of B lymphocytes, a type of white blood cell responsible for fighting infections.The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-525 as a monotherapy.ABBV-525 is an investigational drug being developed for the treatment of B-Cell Malignancies.Study doctors put the participants in groups called treatment arms.Participants will receive ABBV-525 at different doses.Approximately 100 adult participants will be…

Read more